Physician profile

John R Backman

Cardiovascular Disease · Encinitas, CA

NPI 1215905831

$13,505.92

in general payments reported to CMS, 2019-2025

51 companies · $590 in 2025

The $590 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,839.34
Education$95.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $1,160.96 2019-2025
Pfizer INC. $1,118.88 2019-2025
Merck Sharp & Dohme LLC $1,052.48 2021-2025 Verquvo
Amgen INC. $898.60 2019-2025 Repatha, Repatha
Janssen Pharmaceuticals, INC $816.19 2019-2024 Xarelto
Astrazeneca Pharmaceuticals Lp $668.43 2019-2025 Farxiga, Wainua, Brilinta
Sanofi-Aventis U.S. LLC $630.06 2019-2024
Boston Scientific Corporation $562.50 2019-2025 Watchman Access System, Accolade Sr, Watchman Flx
E.R. Squibb & Sons, L.L.C. $558.44 2019-2024 Camzyos, Eliquis
Impulse Dynamics (USA) INC. $502.98 2022-2023 Optimizer
Actelion Pharmaceuticals US, INC. $477.35 2019-2024 Uptravi, Opsumit
Medtronic, INC. $409.08 2023-2025 Linq II, Aurora Ev-Icd Mri Surescan
Abbott Laboratories $406.31 2019-2024 Mitraclip, Thoratec Heartmate 3 Lvas Implant Kit
Novo Nordisk INC $385.13 2021-2024 Rybelsus, Ozempic
Boehringer Ingelheim Pharmaceuticals, INC. $340.84 2019-2025 Jardiance
Show all 51 companies
CompanyGeneral paymentsYearsTop products
Cvrx, INC. $327.06 2022-2024 Barostim Neo System
Esperion Therapeutics, INC. $325.83 2021-2024 Nexletol, Nexlizet
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $309.27 2019-2024 Lifevest
Irhythm Technologies, INC. $236.58 2019-2024 Zio Xt Patch, Zio Monitor
Kiniksa Pharmaceuticals, Ltd. $213.96 2021-2023 Arcalyst
Regeneron Healthcare Solutions, INC. $196.80 2019-2025 Evkeeza
Medtronic Vascular, INC. $192.19 2019
Bardy Diagnostics, INC. $185.00 2020-2022
Abiomed $174.13 2023-2024 Impella
Heartflow, INC. $172.42 2019-2025
Otsuka America Pharmaceutical, INC. $113.06 2019
Chiesi USA, INC. $108.55 2022-2024 Kengreal
Kiniksa Pharmaceuticals International, Plc $99.00 2024 Arcalyst
Amarin Pharma, INC. $93.09 2019-2022
Lexicon Pharmaceuticals, INC. $90.21 2024 Inpefa
Tactile Systems Technology INC $72.56 2019-2025 Nimbl, Flexitouch Plus
Lundbeck LLC $72.04 2019-2020
Daiichi Sankyo INC. $57.85 2022-2023 Injectafer
Kowa Pharmaceuticals America, INC. $54.16 2019-2022
Braemar Manufacturing, LLC $48.42 2019
Philips North America LLC $43.11 2023-2024 (Ck4) Mcot
Gilead Sciences, INC. $42.48 2019
Celgene Corporation $37.54 2023 Camzyos
Kestra Medical Technology Services, INC. $26.01 2024 Assure Wcd
Biotronik INC. $24.45 2022
Alnylam Pharmaceuticals INC. $24.25 2023 Amvuttra
Baxter Healthcare $22.48 2024 Hillrom - Cardiac Ambulatory Monitor
Edwards Lifesciences Corporation $21.21 2024 Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Atricure, INC. $20.95 2022
Scpharmaceuticals INC. $20.51 2023
W. L. Gore & Associates, INC. $17.82 2020
Angiodynamics, INC. $17.73 2021
Trevena, INC. $15.66 2022
Amryt Pharma Holdings Ltd $15.28 2022
Itamar Medical INC $14.06 2022
Allergan, INC. $11.97 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

John R Backman

$13,505.92

in general payments reported 2019-2025

Years
2019-2025
Top company
Novartis Pharmaceuticals Corporation
Context
The $590 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/190853/john-r-backman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.